Simultaneous estimation of nebivolol hydrochloride and valsartan in bulk and capsule dosage form by simultaneous equation method

International Journal of ChemTech Research

Volumn 2, Issue 3, 2010, Pages 1387-1390

  Modiya, Jagadish S ^a   Pandya, Chirag B ^a   Channabasavaraj, K P ^a  

^a BHARATHI COLLEGE OF PHARMACY   (India)

Author keywords

Nebivolol Hydrochloride; Simultaneous estimation; Validation; Valsartan

Indexed keywords

METHANOL; NEBIVOLOL; VALSARTAN;

ACCURACY; ARTICLE; CORRELATION COEFFICIENT; DRUG CAPSULE; DRUG DETERMINATION; MULTIPLE REGRESSION;

EID: 77957372335     PISSN: None     EISSN: 09744290     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Kamp O., Sieswerda G.T. and Visser C.A., Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension, Am. J. Cardiol, 2003, 92, 344-348.
2. Gielen W., Cleophas T.J. and Agrawal R., Nebivolol: A review of its clinical and pharmacological characteristics, Int. J. Clin. Pharmacol. Ther, 2006, 44, 344-357.
3. Gao Y.S., Nagao T., Bond R.A., Jannsens W.J. and Vanhoutte P.M., Nebivolol induces endothelium dependent relaxation of canine coronary artery, J. Cardiovasc. Pharmacol, 1991, 17, 964-969.
4. Nodari S., Metra M. and Dei Cas L., Beta-blocker treatment of patients with diastolic heart failure and arterial hypertension: A prospective, randomized, comparison of the long-term effects of atenolol vs. Nebivolol, Eur. J. Heart. Fail, 2003, 5, 621-627.
5. Pessina A.C., Metabolic effects and safety profile of nebivolol, J. Cardiovasc. Pharmacol, 2001, 38, S33-35.
6. Weber M.A., The role of the new beta-blockers in treating cardiovascular disease, Am. J. Hypertens, 2005, 18, 169S-176S.
7. Poirier L., Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients, J. Hypertens, 2001, 19, 1429-1435.
8. Patel L.J. and Suhagia B.N., RP-HPLC and HPTLC methods for the estimation of nebivolol hydrochloride in tablet dosage form, Ind. J. Pharm Sci, 2007, 69, 594-596.
9. Mario T., George O. and Wilhem S. High speed determination of beta-receptor blocking agents in human urine by liquid chromatography/tandem mass spectrometry, Biomed. Chromatogr, 2001, 15, 393-402.
10. Ramakrishna N.V., Vishwottam K.N., Koteshwara M., Manoj S., Santosh M. and Varma D.P. Rapid quantification of nebivolol in human plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry, J. Pharm. Biomed. Anal, 2005, 39, 1006-1013.
11. Maurer H.H., Tenberken O., Kratzsch C., Weber A.A. and Peters F.T., Screening for library-assisted identification and fully validated quantification of 22 beta-blockers in blood plasma by liquid chromatography-mass spectrometry with atmospheric pressure chemical ionisation, J. Chromatogr. A, 2004, 1058, 169-173.
12. Verma S. and Strauss M., Angiotensin receptor blockers and myocardial infarction, Br. Med. J, 2004, 329, 1248-1249.
13. Senthamil S.P., Veeran G.K., Mandal U., Sam S.W. and Pal T.K., Simultaneous determination of fixed dose combination of nebivolol and valsartan in human plasma by liquid chromatographic-tandem mass spectrometry and its application to pharmacokinetic study, J. Chromatogr. B., 2007, 858, 143-150.
14. Macek J., Klνma J. and Ptαθek P., Rapid determination of valsartan in human plasma by protein precipitation and high-performance liquid chromatography, J. Chromatogr. B., 2006, 832, 169-172.
15. International Conference on Harmonization (ICH), Validation of Analytical Procedures: Text on Validation of Analytical Procedures Q2A, 1994.
16. International Conference on Harmonization (ICH), Validation of Analytical Procedures: Methodology Q2B, 1996.
17. International Conference on Harmonization (ICH), Validation of Analytical Procedures: Text and Methodology Q2 (R1), 2005.